Germany-headquartered Bayer (ETR: BAYN) has entered into a partnership with China-based Changzhou Qianhong Bio-pharma Co., Ltd (SHE: 002550), focusing on the digestive enzyme field. The collaboration aims to explore and promote product development in the digestive tract health sector, with no financial details disclosed.
Focus on Digestive Tract Health and Continued Collaboration
Digestive tract health is a key focus area for Bayer’s consumer health division. An earlier collaboration between Bayer and Qianhong resulted in Hydrotalcite Compound Digestive Enzyme Capsules, an over-the-counter (OTC) drug used to treat gastric disorders such as lack of appetite and indigestion.
Bayer’s Expansion into Cross-Border E-Commerce with SINOTRANS (HK)
In a separate development, Bayer has agreed to collaborate with SINOTRANS (HK) to support the healthy growth of cross-border e-commerce business, which is anticipated to benefit Bayer’s consumer health products.- Flcube.com
